Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:45:24.176Z.
Calculation as of: 2026-10-06T18:45:24.176Z.
Quote observation: 2026-10-06T18:20:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d554412806125b06490580232e6d80b3120c6a72214b764814008bb1d876b03
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Ainos, Inc.
Market Cap
$9.65M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Ainos, Inc. (AIMD) | $9.65M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.75M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.62M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.28M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.24M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.08M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.11M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $8.99M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.38M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
